{"id":"cervavac-as-two-dose-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant HPV L1 virus-like particles (VLPs) that trigger both humoral and cellular immune responses against the major oncogenic HPV types responsible for approximately 70% of cervical cancers. By inducing neutralizing antibodies and T-cell mediated immunity, the vaccine prevents persistent HPV infection and subsequent malignant transformation of cervical epithelial cells.","oneSentence":"Cervavac is a two-dose recombinant protein subunit vaccine that stimulates immune responses against human papillomavirus (HPV) types 16 and 18 to prevent cervical cancer and related precancerous lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:51.276Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of cervical cancer caused by HPV types 16 and 18"},{"name":"Prevention of cervical intraepithelial neoplasia (CIN) and other HPV-related precancerous lesions"}]},"trialDetails":[{"nctId":"NCT06281119","phase":"PHASE3","title":"Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years","status":"NOT_YET_RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-03","conditions":"Human Papillomavirus Infection","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cervavac as two dose regimen","genericName":"Cervavac as two dose regimen","companyName":"Serum Institute of India Pvt. Ltd.","companyId":"serum-institute-of-india-pvt-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cervavac is a two-dose recombinant protein subunit vaccine that stimulates immune responses against human papillomavirus (HPV) types 16 and 18 to prevent cervical cancer and related precancerous lesions. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of cervical intraepithelial neoplasia (CIN) and other HPV-related precancerous lesions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}